Recent News

• 01.09.2026 - Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of the phase 2b FASCINATE-2 trial
• 11.10.2025 - Spatial Computational Histology Stratified Denifanstat Fibrosis Responders in the Phase 2b FASCINATE-2 MASH Trial
• 11.10.2025 - Denifanstat elicited a significant ≥ 2-stage improvement in fibrosis in F3 MASH patients, and improved liver fibrosis and biomarkers in qFibrosis stage 4 MASH patients: secondary analysis of phase 2b FASCINATE-2 trial
• 10.27.2025 - FASN Inhibitor Denifanstat Achieved All Endpoints in the Treatment of Acne Vulgaris: Results from a Phase III Randomised Placebo-Controlled Trial
• 10.01.2025 - Sagimet Biosciences Announces Dosing of First Participants in Phase 1 PK Clinical Trial for Denifanstat and Resmetirom Combination
• 09.24.2025 - Sagimet Biosciences Announces Upcoming Panel Participation at Fierce Biotech Week

Recent Filings

• 12.18.2025 - EX-99.1 EX-99.1
• 12.18.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.18.2025 - 8-K Current report
• 12.17.2025 - 8-K Current report
• 12.17.2025 - EX-99.1 EX-99.1
• 11.21.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.20.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2025 - EX-99.1 EX-99.1
• 11.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]